Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

Plasma glial fibrillary acidic protein levels correlate with unfavourable imaging measures in Radiologically Isolated Syndrome
Multiple Sclerosis
P1 - Poster Session 1 (8:00 AM-9:00 AM)
3-003

Radiologically isolated syndrome (RIS) describes people without previous or current MS symptoms who have characteristic lesions on brain MRI seen in people with MS (pwMS). There are no clear evidence-based guidelines as to how to manage pwRIS. Imaging and blood-based biomarkers carry promise as potential tools to guide treatment decisions in pwRIS. We have previously shown that the majority of pwRIS show a high proportion of white matter lesions (WMLs) demonstrating the central vein sign (CVS) and have at least one paramagnetic rim lesion, an imaging biomarker of chronic, active WMLs in MS. (PRL). Glial fibrillary acidic protein (GFAP) is a potential blood biomarker being evaluated in MS. However, GFAP has not been studied in pwRIS, particularly in relation to the CVS and PRLs.

To study whether plasma GFAP (pGFAP) levels correlate with imaging measures and can be used as a prognostic blood biomarker in people with RIS (pwRIS).

32 pwRIS underwent 3T brain and cervical spinal cord MRI and had pGFAP levels measured on an HD-1 Simoa platform (Quanterix). Spearmans correlation coefficient was used to evaluate correlations.

pGFAP levels correlated positively with the number of black holes, CVS+WMLs, and PRLs (p<0.05 using Spearman's correlation coefficient).

This pilot study is the first to demonstrate that pGFAP levels correlate positively with the number of: black holes, CVS+WMLs, and PRLs in pwRIS. Given the established relationships between black holes, PRLs and MS disease progression, pwRIS with high pGFAP levels may be at increased risk of developing clinical MS and disability over time. Prospective validation is underway to confirm the prognostic value of GFAP in pwRIS.

Authors/Disclosures
Raphael Schneider, MD (St. Michael'S Hospital)
PRESENTER
Dr. Schneider has nothing to disclose.
Koroboshka Brand-Arzamendi, Other (St Michael's Hospital) Mrs. Brand-Arzamendi has nothing to disclose.
Timothy R. Lim Timothy R. Lim has nothing to disclose.
Lisa Eunyoung Lee Lisa Eunyoung Lee has nothing to disclose.
Melanie Guenette Melanie Guenette has nothing to disclose.
Suradech Suthiphosuwan, MD (St Michael’s Hospital, Unity Health) Dr. Suthiphosuwan has nothing to disclose.
Aditya Bharatha Aditya Bharatha has nothing to disclose.
Jiwon Oh, MD, FAAN (St Michael's Hospital) Dr. Oh has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche. The institution of Dr. Oh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen-Idec. Dr. Oh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BMS. Dr. Oh has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for EMD-Serono. Dr. Oh has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi-Genzyme. Dr. Oh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Oh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly. Dr. Oh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Horizon Therapeutics. Dr. Oh has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Oh has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen-Idec. Dr. Oh has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi-Genzyme. The institution of Dr. Oh has received research support from Biogen-Idec. The institution of Dr. Oh has received research support from Roche.